Raymond James Financial
NRIX icon

Raymond James Financial’s Nurix Therapeutics NRIX Stock Holding History

Raymond James Financial’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.4M Buy
593,262
+239,529
+68% +$4.08M ﹤0.01% 1819
2026
Q1 		$5.2M Buy
+353,733
New +$5.87M ﹤0.01% 2559
2025
Q3 		– Sell
-1,618
Closed -$18.4K – 6127
2025
Q2 		$18.4K Buy
+1,618
New +$17.5K ﹤0.01% 5634
2025
Q1 		– Sell
-54,453
Closed -$1.03M – 4909
2024
Q4 		$1.03M Buy
+54,453
New +$1.25M ﹤0.01% 3435

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Raymond James Financial's NRIX Position: Q2 2026 in Review

Raymond James Financial increased its Nurix Therapeutics (NRIX) stake by 68% in Q2 2026, buying an estimated $4.08M and bringing the position to 593,262 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1819.

Raymond James Financial first reported a position in NRIX in Q4 2024 and has held it in 4 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Raymond James Financial held 593,262 shares of Nurix Therapeutics worth $14.4M as of Q2 2026.
  • Raymond James Financial bought 239,529 Nurix Therapeutics shares in Q2 2026, an estimated $4.08M.
  • Nurix Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #1819 holding.
  • Raymond James Financial first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.